Daniela Weisenberger

Josef Schneider Str. 2
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists.

A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists.

Journal: Cell death & disease

Published: August 06, 2025

Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins.

Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins.

Journal: Cell chemical biology

Published: November 30, 2024

Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism.

Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism.

Journal: Theranostics

Published: March 17, 2023

CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.

CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.

Journal: mAbs

Published: August 26, 2020

Correction: Binding studies of TNF receptor superfamily (TNFRSF) receptors on intact cells.

Correction: Binding studies of TNF receptor superfamily (TNFRSF) receptors on intact cells.

Journal: The Journal of biological chemistry

Published: August 10, 2020

TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity.

TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity.

Journal: Cell death & disease

Published: October 25, 2018

Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.

Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.

Journal: Cancer immunology, immunotherapy : CII

Published: November 13, 2015

Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Journal: The Journal of biological chemistry

Published: August 07, 2015

TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes.

TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 07, 2013

Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Journal: The Journal of biological chemistry

Published: March 28, 2013

Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).

Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).

Journal: The Journal of biological chemistry

Published: November 15, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026